Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeldesivir in Pediatric COVID-19
NCT05996744Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Dec 2023
- Primary completion
- Feb 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of obeldesivir in coronavirus disease 2019 (COVID-19) (7 cohorts), sponsored by Gilead Sciences. Primary endpoints: Plasma Concentration of GS-441524, Metabolite of Obeldesivir at Day 5, Percentage of Participants Experiencing Treatment-Emergent Adverse Events at Day 35 and 1 more. Started Dec 2023; status: terminated.
02
Drugs
obeldesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05996744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996744.